Overview

Phase 1 Study of ACE-083 in Healthy Subjects

Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and tolerability of single and multiple doses of ACE-083 as a local injection into selected skeletal muscles of healthy subjects. The study will also determine the amount of ACE-083 that reaches the systemic circulation following local administration. Additionally, the study will assess whether local administration into skeletal muscle results in an increase in the size and/or strength of the injected muscle.
Phase:
Phase 1
Details
Lead Sponsor:
Acceleron Pharma Inc.
Acceleron Pharma, Inc.